1081 @entity1 treated with @entity583 between 1990-1995 were investigated retrospectively, 652 (60.3%) of the @entity1 were male and 429 (39.7%) were female. 154 (14.2%) @entity1 had an early, while 927 (85.5%) @entity1 had late @entity583 . Of the @entity1 with early @entity583 52.3% were smokers, 45.2% had positive family history for @entity299 or @entity583 . The lipid parameters were analysed in detail, because 83.3% of the @entity1 were hyperlipoproteinaemic. The mean @entity165 level was 6.91 +/- 1.2 mmol/l, the HDL-C level was 1.19 +/- 0.38 mmol/l, the @entity412 level was 2.66 +/- 1.8 mmol/l, the LDL-C level was 4.71 +/- 1.2 mmol/l. The serum LDL-C and the HDL-C levels of the @entity1 with early @entity583 were compared to the desirable levels suggested for secondary prevention. Only 7.2% of the male @entity1 had a @entity165 level below 5.2 mmol/l, while all female @entity1 @entity165 levels were above 5.2 mmol/l. Of the male @entity1 53.6%, while 78.6% of females had lower @entity412 levels than 2.3 mmol/l 78,6% of the male @entity1 had higher protective HDL-C level in the optimal range (> 1.1 mmol/l). 12.5 percent of the male @entity1 had an LDL-C level lower than the value targeted by secondary prevention (3.0 mmol/l), while all of the female @entity1 LDL-C levels were higher. The authors emphasize the importance of secondary prevention and a more widespread use of lipid lowering treatment for @entity1 after @entity583 .

[Lipid lowering treatment in secondary prevention following XXXX ].

@entity1 :: ('9606', 'Species') :: ['patients'] @entity412 :: ('CHEBI:17855', 'Chemical') :: ['triglyceride'] @entity299 :: ('MESH:D006331', 'Disease') :: ['ischaemic heart disease'] @entity583 :: ('MESH:D009203', 'Disease') :: ['myocardial infarction', 'acute myocardial infarction'] @entity165 :: ('MESH:D002784', 'Chemical') :: ['cholesterol']
@entity583 :: (MESH:D009203,Disease) :: ['myocardial infarct']
